This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Acelarin

NuCana Biomed Ltd.

Drug Names(s): NUC1031, NUC-1031, MTL-007, MTL007

Description: NUC-1031 (Acelarin) is a prodrug of gemcitabine, a nucleoside analogue that inhibits DNA synthesis.

NUC-1031 is designed to overcome drug resistance due to its nucleoside transporter-independent cellular uptake, activity independent of deoxycytidine kinase, and resistance to cytidine deaminase inactivation.

Deal Structure: NuCana and Morvus
In November 2009, Morvus and NuCana announced that an agreement has been signed by which Morvus has granted to NuCana an exclusive, world-wide, licence with rights to develop its ProTide technology for the enhancement of nucleoside analogues. Under the new agreement NuCana will fund the project and take responsibility for the commercial and clinical development strategy. The agreement grants Morvus certain rights and future milestone payments and royalties.

Partners: Morvus Technology Limited


Acelarin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug